Puma Biotechnology (PBYI) Free Cash Flow (2010 - 2026)
Puma Biotechnology's (PBYI) quarterly Free Cash Flow came in at $15.4 million in Q1 2026, up 334.13% YoY from $3.6 million in Q1 2025, and up 6.65% on a QoQ basis from $14.5 million in Q4 2025.
Puma Biotechnology (PBYI) Free Cash Flow (2010 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 17 years of Free Cash Flow data on file, last reported at $15.4 million in Q1 2026.
- Quarterly Free Cash Flow rose 334.13% year-over-year to $15.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $53.6 million (up 71.96% YoY) and the FY2025 annual result came in at $41.7 million, up 7.38% from the prior year.
- Free Cash Flow grew to $15.4 million in Q1 2026, from $14.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $17.3 million in Q3 2022 to a low of -$26.9 million in Q1 2022.
- A 5-year average of $6.3 million and a median of $10.4 million in 2023 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow sank 18648.65% — and 2025, when it soared 1289.68%.
- Tracing PBYI's Free Cash Flow over 5 years: stood at $7.7 million in 2022, then surged by 35.74% to $10.4 million in 2023, then soared by 49.3% to $15.6 million in 2024, then decreased by 7.17% to $14.5 million in 2025, then rose by 6.65% to $15.4 million in 2026.
- The last three Free Cash Flow figures came in at $15.4 million (Q1 2026), $14.5 million (Q4 2025), and $9.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 1.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.62 Mn |
| Jun 30, 2026 | 1.62 Mn |
| Mar 31, 2026 | 15.42 Mn |
| Mar 31, 2026 | 15.42 Mn |
| Dec 31, 2025 | 14.46 Mn |
| Dec 31, 2025 | 14.46 Mn |
| Sep 30, 2025 | 9.59 Mn |
| Sep 30, 2025 | 9.59 Mn |
| Jun 30, 2025 | 14.13 Mn |
| Jun 30, 2025 | 14.13 Mn |
| Mar 31, 2025 | 3.55 Mn |
| Mar 31, 2025 | 3.55 Mn |
| Dec 31, 2024 | 15.57 Mn |
| Dec 31, 2024 | 15.57 Mn |
| Sep 30, 2024 | 11.03 Mn |
| Sep 30, 2024 | 11.03 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Jun 30, 2024 | 1.02 Mn |
| Mar 31, 2024 | 11.25 Mn |
| Mar 31, 2024 | 11.25 Mn |